STEPHEN NORTHRUP

Issues related to modernizing access to prescribing information.

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs. H.R.1503, Prescription Information Modernization Act of 2023. S.127, Pharmacy Benefit Manager Transparency Act of 2023. S.775, Increasing Transparency in Generic Drug Applications Act. Issues related to President's Emergency Plan For Aids Relief (PEPFAR). H.R.5378, Lower Costs, More Transparency Act.

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services.

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding, National Institutes of Health funding, reauthorization of the Pandemic and All-Hazards Preparedness Act (S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4420, Preparedness and Response Reauthorization Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act), and Biosecurity Infrastructure for Operational Early Warning Act (discussion draft).

Issues related to IP and advanced technology manufacturing; The CHIPS and Science Act of 2022 (P.L.117-167).

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness. H.R.2389/S.1302, Resident Physician Shortage Reduction Act of 2023. H.R.2665, Supporting Safety Net Hospitals Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act, S.2333, Pandemic and All-Hazards Preparedness and Response Act, H.R.4420, Preparedness and Response Reauthorization Act, H.R.4421, Preparing for All Hazards and Pathogens Reauthorization Act.

S.665, Conrad State 30 and Physician Access Reauthorization Act; physician workforce and immigration issues.

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; H.R.1503, Prescription Information Modernization Act of 2023; S.127, Pharmacy Benefit Manager Transparency Act of 2023; S.775, Increasing Transparency in Generic Drug Applications Act. Issues related to President's Emergency Plan For Aids Relief (PEPFAR).

Issues related to modernizing access to prescribing information.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; H.R.1629, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2023; H.R.1628, CBD Product Safety and Standardization Act of 2023.

Tax treatment of nutritional and dietary supplements.

Issues related to IP and advanced technology manufacturing; The CHIPS and Science Act of 2022 (P.L.117-167).

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services.

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding, National Institutes of Health funding, reauthorization of the Pandemic and All-Hazards Preparedness Act, and Biosecurity Infrastructure for Operational Early Warning Act (discussion draft).

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805, Leos Law. Reauthorization of the Pandemic and All-Hazards Preparedness Act. Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R.830, S.1375, The HELP Copays Act.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, kidney research and development, and long COVID syndrome; FY 2024 budget and appropriations process.

Issues related to excise tax on university investment income. Implementation of Tax Cuts and Jobs Act (P.L.115-97).

Issues related to VA medical centers.

Medicare and Medicaid funding for graduate medical education.

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; Reauthorization of the Pandemic and All-Hazards Preparedness Act; H.R.2389/S.1302, Resident Physician Shortage Reduction Act of 2023; H.R.2665, Supporting Safety Net Hospitals Act.

S.665, Conrad State 30 and Physician Access Reauthorization Act; physician workforce and immigration issues.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services). Policies impacting Medicare coverage and reimbursement for clinical laboratory services. FDA regulation of clinical laboratory services. Coronavirus impact and response. H.R.2377/S.1000, Saving Access to Laboratory Services Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R.3791, Improving DATA in Public Health Act. H.R.3248, Diagnostic Lab Testing Transparency Act. FY 2024 budget and appropriations process.

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R.1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R.2673, The American Innovation and R&D Competitiveness Act.

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; H.R.1503, Prescription Information Modernization Act of 2023; S.127, Pharmacy Benefit Manager Transparency Act of 2023; S.775, Increasing Transparency in Generic Drug Applications Act. Issues related to President's Emergency Plan For Aids Relief (PEPFAR).

Issues related to modernizing access to prescribing information.

Issues related to IP and advanced technology manufacturing; The CHIPS and Science Act of 2022 (P.L.117-167).

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding, National Institutes of Health funding, and reauthorization of the Pandemic and All-Hazards Preparedness Act.

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; H.R.1629, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2023; H.R.1628, CBD Product Safety and Standardization Act of 2023.

Tax treatment of nutritional and dietary supplements.

Issues related to excise tax on university investment income. Implementation of Tax Cuts and Jobs Act (P.L.115-97).

Issues related to VA medical centers.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, kidney research and development, and long COVID syndrome; FY 2024 budget and appropriations process.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services). Policies impacting Medicare coverage and reimbursement for clinical laboratory services. FDA regulation of clinical laboratory services. Coronavirus impact and response. Saving Access to Laboratory Services Act (draft legislation). Reauthorization of the Pandemic and All-Hazards Preparedness Act.

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; H.R.2389, Resident Physician Shortage Reduction Act of 2023; Reauthorization of the Pandemic and All-Hazards Preparedness Act.

Medicare and Medicaid funding for graduate medical education.

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization.

Issues related to infant formula and medical nutrition. Issues related to FDA reorganization of food regulation.

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Prescription Drug User Fee Act (PDUFA) Reauthorization; Generic Drug User Fee Amendments (GDUFA) Reauthorization; H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.6973/S.4351, Enhanced Access to Affordable Medicines Act of 2022; H.R.7032/S.4338, Increasing Transparency in Generic Drug Applications Act of 2022; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.7559, Prescription Information Modernization Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.

Issues related to modernizing access to prescribing information; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); H.R.2617, Consolidated Appropriations Act, 2023.

Issues related to infant formula and medical nutrition; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); S.4090, Dietary Supplement Listing Act of 2022; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5030/S.2706, DIVERSE Trials Act; H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding; H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.

Issues related to IP and advanced technology manufacturing; The CHIPS and Science Act of 2022 (P.L.117-167).

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R.1730/S.670, The Speeding Therapy Access Today (STAT) Act of 2021; H.R.2617, Consolidated Appropriations Act, 2023.

Issues related to Research and Development Tax Amortization.

Issues related VA medical centers; H.R.5721, VA Infrastructure Powers Exceptional Research Act of 2021.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; Advanced Research Project Agency-Health issues; S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, kidney research and development, and long COVID syndrome; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); H.R.2617, Consolidated Appropriations Act, 2023.

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies.

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act; H.R.5721, VIPER Act of 2021; H.R.8188/S.4449, Saving Access to Laboratory Services Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services), H.R.8188, To amend title XVIII of the Social Security Act to improve the accuracy of market-based Medicare payment for clinical diagnostic laboratory services, to reduce administrative burdens in the collection of data, and for other purposes; Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); H.R.8188/S.4449, Saving Access to Laboratory Services Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; H.R.6000, Cures 2.0 Act; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); S.3799, PREVENT Pandemics Act; H.R.8152, American Data Privacy and Protection Act; H.R.6202, Telehealth Extension Act of 2021; H.R.2617, Consolidated Appropriations Act, 2023.

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Prescription Drug User Fee Act (PDUFA) Reauthorization; Generic Drug User Fee Amendments (GDUFA) Reauthorization; H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.6973/S.4351, Enhanced Access to Affordable Medicines Act of 2022; H.R.7032/S.4338, Increasing Transparency in Generic Drug Applications Act of 2022; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.7559, Prescription Information Modernization Act of 2022.

Issues related to modernizing access to prescribing information; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169).

Issues related to infant formula and medical nutrition; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); S.4090, Dietary Supplement Listing Act of 2022; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5030/S.2706, DIVERSE Trials Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Issues related to FTC, mergers, antitrust.

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding; H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R.1730/S.670, The Speeding Therapy Access Today (STAT) Act of 2021.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; Advanced Research Project Agency-Health issues; S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021.

Issues related VA medical centers; H.R.5721, VA Infrastructure Powers Exceptional Research Act of 2021.

Issues related to excise tax on university investment income. Implementation of Tax Cuts and Jobs Act (P.L.115-97).

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180).

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services), H.R.8188, To amend title XVIII of the Social Security Act to improve the accuracy of market-based Medicare payment for clinical diagnostic laboratory services, to reduce administrative burdens in the collection of data, and for other purposes, S.4449, Saving Access to Laboratory Services Act; Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022, H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); S.3799, PREVENT Pandemics Act; H.R.8152, American Data Privacy and Protection Act.

Issues related to infant formula and medical nutrition.

Issues related to modernizing access to prescribing information; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, Senate); FY2022 Budget Reconciliation (H.R.5376).

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Prescription Drug User Fee Act (PDUFA) Reauthorization; Generic Drug User Fee Amendments (GDUFA) Reauthorization; H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6973/S.4351, Enhanced Access to Affordable Medicines Act of 2022; H.R.7032/S.4338, Increasing Transparency in Generic Drug Applications Act of 2022; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, Senate); H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; S.4090, Dietary Supplement Listing Act of 2022.

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6000, Cures 2.0 Act; H.R.5030/S.2706, DIVERSE Trials Act; FY2022 Budget Reconciliation (H.R.5376); H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Issues related to FTC, mergers, antitrust.

Issues related to IP and advanced technology manufacturing; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; PDUFA Reauthorization; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation (H.R.5376); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.

Policies related to custom therapeutics for ultra-rare diseases; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, Senate).

Issues related VA medical centers; H.R.5721, VA Infrastructure Powers Exceptional Research Act of 2021.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, kidney research and development, and long COVID syndrome; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, Senate); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, Senate); FY2022 Budget Reconciliation (H.R.5376).

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies.

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Budget Reconciliation (H.R.5376); H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services), H.R.8188, To amend title XVIII of the Social Security Act to improve the accuracy of market-based Medicare payment for clinical diagnostic laboratory services, to reduce administrative burdens in the collection of data, and for other purposes, S.4449, Saving Access to Laboratory Services Act; Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); MDUFA Reauthorization, H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation (H.R.5376); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, Senate); S.3799, PREVENT Pandemics Act.

Issues related to modernizing access to prescribing information; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2022 Budget Reconciliation (H.R.5376).

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Prescription Drug User Fee Act (PDUFA) Reauthorization; Generic Drug User Fee Amendments (GDUFA) Reauthorization; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6973, Enhanced Access to Affordable Medicines Act of 2022; H.R.7032, Increasing Transparency in Generic Drug Applications Act of 2022.

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations.

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; MDUFA Reauthorization; PDUFA Reauthorization; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6000, Cures 2.0 Act; H.R.5030/S.2706, DIVERSE Trials Act; FY2022 Budget Reconciliation (H.R.5376); H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act.

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2022 Budget Reconciliation (H.R.5376); S.3799, PREVENT Pandemics Act.

Issues related to IP and advanced technology manufacturing; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.

Policies related to custom therapeutics for ultra-rare diseases; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; PDUFA Reauthorization; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation (H.R.5376); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, kidney research and development, and long COVID syndrome; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2022 Budget Reconciliation (H.R.5376).

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies.

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; Implementation of Affordable Care Act (P.L.111-148); Implementation of H.R.748, CARES Act (P.L.116-136); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Budget Reconciliation (H.R.5376); H.R.5585, Advanced Research Project Agency-Health Act; S.3799, PREVENT Pandemics Act.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services); Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); Implementation of H.R.748, CARES Act (P.L.116-136); MDUFA Reauthorization; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation (H.R.5376); FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); Y2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; S.3799, PREVENT Pandemics Act.

Issues impacting the importation and certification of Patagonian Toothfish

Legislative and regulatory services related to the Tax Injunction Act, 28 U.S. Code Section 1341.

Policies related to custom therapeutics for ultra-rare diseases.

Issues related to modernizing access to prescribing information; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599).

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6000, Cures 2.0 Act; H.R.5030/S.2706, DIVERSE Trials Act; FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502/S.3062); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Issues related to FTC, mergers, antitrust.

Issues related to the development of therapies for rare diseases and sleep disorders; Issues related to drug pricing; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.6000, Cures 2.0 Act; FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, kidney research and development, and long COVID syndrome; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502/S.3062); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Issues related to excise tax on university investment income. Implementation of Tax Cuts and Jobs Act (P.L.115-97).

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; S.610, Protecting Medicare and American Farmers from Sequester Cuts Act (P.L.117-71).

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; Implementation of Affordable Care Act (P.L.111-148); Implementation of H.R.748, CARES Act (P.L.116-136); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; H.R.6000, Cures 2.0 Act; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376); S.610, Protecting Medicare and American Farmers from Sequester Cuts Act (P.L.117-71).

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services); Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); Implementation of H.R.748, CARES Act (P.L.116-136); S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; H.R.6000, Cures 2.0 Act; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502/S.3062); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376); S.610, Protecting Medicare and American Farmers from Sequester Cuts Act (P.L.117-71).

Issues related to modernizing access to prescribing information; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599).

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; CURES 2.0 Act discussion draft; H.R.5030/S.2706, DIVERSE Trials Act; FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding; Implementation of H.R.748, CARES Act (P.L.116-136); CURES 2.0 discussion draft; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Issues related to the development of therapies for rare diseases and sleep disorders; Issues related to drug pricing; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; CURES 2.0 Act discussion draft; FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Issues related to excise tax on university investment income. Implementation of Tax Cuts and Jobs Act (P.L.115-97).

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, kidney research and development, and long COVID syndrome; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; Implementation of Affordable Care Act (P.L.111-148); Implementation of H.R.748, CARES Act (P.L.116-136); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; CURES 2.0 Act discussion draft; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services); Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); Implementation of H.R.748, CARES Act (P.L.116-136); S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021; CURES 2.0 Act discussion draft; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376).

Issues affecting access to contraception.

Issues affecting access to contraception.

Issues related to the development of therapies for rare diseases and sleep disorders; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.

Issues related to modernizing access to prescribing information; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act.

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.

Discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding; H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; CURES 2.0 discussion draft; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021.

Million Veterans Program (MVP), issues related to precision medicine.

Issues related to FTC, mergers, antitrust.

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Issues related to excise tax on university investment income and tax on high cost health plans. Implementation of Tax Cuts and Jobs Act (P.L.115-97).

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021.

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services); Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021.

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; public health and pandemic preparedness; surprise billing; Implementation of Affordable Care Act (P.L.111-148); Implementation of H.R.748, CARES Act (P.L.116-136); S.834/H.R.2256, Resident Physician Shortage Reduction Act of 2021; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); CURES 2.0 Act discussion draft; S.2209/H.R.4128, Verifying Accurate Leading-edge IVCT Development Act 6 of 2021.

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); CURES 2.0 discussion draft; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.

Issues affecting access to contraception.

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.153, Protecting Consumer Access to Generic Drugs Act of 2021; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Tax treatment of nutritional and dietary supplements.

FDA regulations and legislation affecting dietary supplements, medical foods and other natural products; regulations and legislation related to foods and dietary supplements containing CBD; Coronavirus impact and response; H.R.841, Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products; Coronavirus impact and response; social determinants of health; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.5663/S.4225, Safeguarding Therapeutics Act (P.L.116-304); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement. Discussions related to CURES 2.0 discussion draft. Discussions related to CDC surveillance funding and National Institutes of Health funding; H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act.

Million Veterans Program (MVP), issues related to precision medicine.

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services.

Issues related to the development of therapies for rare diseases and sleep disorders.

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, animal research, childhood nutrition, vaccines and immunizations; policies impacting Medicare coverage and reimbursement for clinical laboratory services; Coronavirus impact and response; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Issues related to neglected tropical diseases, space biomedical research, medical schools, health research, childhood nutrition, and kidney research and development; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act.

Support research relief at federal science agencies due to COVID pandemic; Support emergency funding to provide relief for federal research agencies; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Policies impacting Medicare coverage and reimbursement for clinical laboratory services; Medicare and Medicaid funding for graduate medical education; Medicaid safety-net issues; Coronavirus impact and response; surprise billing; Implementation of Affordable Care Act (P.L.111-148); Implementation of H.R.748, CARES Act (P.L.116-136); S.834, A bill to amend title XVIII of the Social Security Act to provide for the distribution of additional residency positions, and for other purposes; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Implementation of Protecting Access to Medicare Act of 2014, P.L.113-93 (changes to reimbursement for clinical laboratory services); Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response; Surprise billing; Implementation of H.R.3584/S.3049, Laboratory Access for Beneficiaries Act (P.L.116-94); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Dissemination of pharmacoeconomic information; Coronavirus impact and response; drug shortages; policies impacting Medicare coverage and reimbursement for prescription drugs; Implementation of H.R.748, CARES Act (P.L.116-136); H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).

Legislation and regulations related to pharmaceuticals and medical products, and access to affordable medicines; Coronavirus impact and response; pharmaceutical supply chain; policies impacting Medicare coverage and reimbursement for prescription drugs; H.R.938, BLOCKING Act of 2019; H.R.1499, Protecting Consumer Access to Generic Drugs Act of 2019; H.R.5444, Lower Insulin Costs Now Act; Implementation of H.R.6201, Families First Coronavirus Response Act (P.L.116-127); Implementation of H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; Implementation of H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139); H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).